Archimedes
Rick Barnhill is a seasoned technology executive currently serving as Chief Technology Officer at Archimedes, where responsibilities include developing and executing technology strategies aligned with business goals. Previously, Rick held senior roles at i3 Verticals, including SVP of Global IT Delivery and Chief of Staff to the CTO, managing a significant P&L budget and overseeing IT service delivery and compliance. Rick's extensive experience includes pivotal positions at Ericsson, directing technology operations and managing high-value projects, as well as consulting for a private equity firm to transition a publicly traded technology service provider. With a solid educational background from Harvard University and Keller Graduate School of Management, Rick specializes in information management systems and cybersecurity.
This person is not in any teams
Archimedes
Specialty drug spend is the single fastest growing healthcare expense. Recognizing the potential clinical value of these drugs, plan sponsors want to provide them to their enrollees—but to maintain an affordable, sustainable benefit in this rapidly changing environment, they must also control costs. To do this, plan sponsors need quantitative information about which strategies work to target drugs to those in need of them and they must minimize use of clinically ineffective therapies and reduce waste. However, the guidance and services provided to plan sponsors to achieve these goals is not always objective or complete. Recognizing these challenges, Archimedes offers specialty drug management solutions for health plans, TPAs, employers, labor groups, and other plan sponsors across the U.S, without any potential conflicted financial relationships with specialty pharmacies or PBMs. Like the scientist and inventor who provided the inspiration for our name, we leverage an unmatched combination of analytic expertise, technological capabilities, experience, and pragmatism to provide plan sponsors with the support that they really need to control the growing cost of specialty drugs across the pharmacy and medical benefits. Fundamental to our business is the belief that full visibility into the economics and clinical performance of a specialty drug program is critical to making informed decisions concerning specialty drug management.